Christopher Trotta
Company: PTC Therapeutics
Job title: Senior Vice President - Biology
Bio:
Chris earned a PhD in biochemistry and molecular biology from the California Institute of Technology where he studied tRNA splicing in the lab of John Abelson. He then pursued a Damon Runyon postdoctoral fellowship focusing on ribosome transport from the nucleus, in the lab of James Dahlberg at the University of Wisconsin-Madison. Following his postdoc, Chris joined PTC Therapeutics as a Scientist. As head of PTC’s discovery efforts, Chris spearheaded the discovery of small molecule modulators of gene expression. Chris has contributed to numerous programs at PTC, notably the discovery and development of votoplam (PTC518), an oral therapy in clinical trials for the treatment of Huntington’s Disease. As Senior Vice President of Discovery Biology, Chris currently leads the biology team to advance the PTSeek splicing platform at PTC.
Seminars:
Opening Remarks 8:45 am
• Highlight past and ongoing efforts to develop RNA-targeted therapeutics • Explore the history and advancement of splicing modifiers as the cornerstone in RNA-targeted discovery • Provide a meeting roadmap, showcasing the exciting science that stems from foundational clinical successes in RNA-targeted therapeutic developmentRead more
day: Conference Day One